Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Phibro Animal Health Corporation's quarterly P/E stands at 13.9x, down 78.8% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 21.4% YoY to 8.3x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 36.27 | 13.94 | 15.56 | 15.20 | 10.47 | 65.63 | 33.12 | 225.40 | 15.39 | 96.50 | — | 12.23 | 15.32 |
| — | -78.8% | -53.0% | -93.3% | -32.0% | -32.0% | — | +1742.7% | +0.5% | +418.1% | — | -54.0% | +35.2% | |
| P/S Ratio | 1.35 | 1.02 | 1.14 | 0.69 | 0.62 | 0.69 | 0.88 | 0.62 | 0.50 | 0.47 | 0.56 | 0.54 | 0.63 |
| — | +48.0% | +29.5% | +10.3% | +25.6% | +47.3% | +57.0% | +14.3% | -21.2% | -15.5% | -3.4% | -28.3% | -25.1% | |
| P/B Ratio | 6.15 | 4.60 | 5.31 | 3.64 | 3.27 | 3.46 | 3.54 | 2.65 | 1.94 | 1.73 | 1.89 | 1.96 | 2.28 |
| — | +32.9% | +50.1% | +37.4% | +68.5% | +100.0% | +86.6% | +34.8% | -14.9% | -14.4% | -7.6% | -33.5% | -24.7% | |
| P/FCF | 41.82 | 46.34 | — | 31.96 | 6.14 | — | 75.18 | 11.06 | 78.10 | 5.69 | 14.82 | 14.84 | — |
| — | — | — | +188.9% | -92.1% | — | +407.2% | -25.5% | — | — | — | — | — | |
| EV / EBITDA | 15.65 | 8.35 | 9.74 | 9.39 | 8.56 | 10.63 | 12.86 | 10.27 | 8.56 | 9.64 | 30.46 | 7.91 | 10.18 |
| — | -21.4% | -24.3% | -8.5% | +0.0% | +10.2% | -57.8% | +29.8% | -15.9% | -4.8% | +179.4% | -15.4% | -5.7% | |
| EV / EBIT | 22.12 | 10.33 | 11.89 | 13.41 | 10.18 | 28.16 | 19.31 | 23.35 | 13.61 | 26.44 | — | 9.59 | 13.89 |
| — | -63.3% | -38.4% | -42.6% | -25.2% | +6.5% | — | +143.4% | -2.0% | +77.4% | — | -48.8% | +38.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Phibro Animal Health Corporation's operating margin was 14.6% in Q2 2026, up 1.4 pp QoQ and up 6.3 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 11.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 7.7% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.9% | 35.5% | 32.9% | 29.0% | 30.1% | 32.9% | 32.1% | 31.9% | 30.2% | 31.5% | 29.3% | 30.1% | 30.7% |
| — | +7.7% | +2.7% | -8.9% | -0.6% | +4.7% | +9.5% | +6.1% | -1.7% | -0.6% | -0.8% | -2.2% | +2.9% | |
| Operating Margin | 8.5% | 14.6% | 13.2% | 8.9% | 9.6% | 8.3% | 6.8% | 6.7% | 7.6% | 6.3% | -0.3% | 9.3% | 7.6% |
| — | +76.3% | +93.7% | +32.1% | +27.3% | +31.4% | +2265.7% | -27.7% | +0.2% | -3.0% | -105.3% | +3.9% | -5.7% | |
| Net Margin | 3.7% | 7.3% | 7.3% | 4.5% | 6.0% | 1.0% | 2.7% | 0.3% | 3.2% | 0.5% | -3.5% | 4.5% | 4.1% |
| — | +613.0% | +172.2% | +1552.1% | +88.0% | +102.1% | +177.3% | -93.9% | -21.9% | -82.7% | -308.9% | +53.7% | -44.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 17.8% | 8.5% | 8.9% | 6.2% | 8.1% | 1.3% | 2.7% | 0.3% | 3.1% | 0.5% | -2.9% | 4.1% | 3.7% |
| — | +576.4% | +228.0% | +2087.1% | +162.0% | +169.1% | +193.9% | -93.1% | -16.3% | -82.7% | -296.5% | +46.5% | -46.8% | |
| ROA | 4.1% | 2.0% | 1.9% | 1.3% | 1.6% | 0.3% | 0.7% | 0.1% | 0.9% | 0.1% | -0.8% | 1.2% | 1.0% |
| — | +595.5% | +169.8% | +1577.1% | +86.3% | +115.1% | +186.5% | -93.5% | -17.3% | -82.6% | -301.9% | +46.5% | -48.0% | |
| ROIC | 9.8% | 3.9% | 3.6% | 2.6% | 2.6% | 2.3% | 1.9% | 1.9% | 2.0% | 1.6% | -0.1% | 2.4% | 1.9% |
| — | +73.4% | +93.2% | +36.2% | +29.2% | +44.4% | +2657.2% | -19.9% | +5.3% | -7.4% | -104.8% | -9.5% | -16.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Phibro Animal Health Corporation's Debt/EBITDA ratio is 11.5x, down from 12.9x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.67 | 2.33 | 2.52 | 2.67 | 2.89 | 3.20 | 1.98 | 2.05 | 1.94 | 1.89 | 1.90 | 1.81 | 1.90 |
| — | -27.3% | +27.2% | +30.2% | +49.5% | +68.8% | +4.3% | +13.4% | +1.9% | -0.6% | -0.9% | +0.7% | +11.4% | |
| Debt / EBITDA | 4.88 | 11.49 | 12.93 | 16.51 | 16.69 | 21.28 | 19.17 | 19.03 | 17.96 | 20.85 | 63.64 | 15.77 | 19.14 |
| — | -46.0% | -32.6% | -13.2% | -7.1% | +2.0% | -69.9% | +20.7% | -6.2% | -0.8% | +180.0% | +4.9% | +16.1% | |
| Current Ratio | 2.76 | 3.05 | 3.09 | 2.76 | 2.91 | 3.20 | 3.23 | 2.94 | 3.16 | 3.12 | 3.39 | 3.33 | 3.54 |
| — | -4.6% | -4.1% | -6.2% | -7.8% | +2.4% | -4.8% | -11.5% | -10.8% | -10.0% | +2.6% | +12.2% | +21.3% | |
| Quick Ratio | 1.25 | 1.22 | 1.35 | 1.25 | 1.23 | 1.37 | 1.69 | 1.64 | 1.67 | 1.60 | 1.77 | 1.75 | 1.77 |
| — | -10.7% | -20.1% | -24.0% | -26.2% | -14.4% | -4.8% | -6.3% | -5.9% | -8.5% | +5.6% | +8.8% | +11.7% | |
| Interest Coverage | 3.04 | 4.17 | 3.69 | 3.82 | 2.96 | 1.53 | 2.18 | 2.12 | 1.97 | 0.96 | -0.72 | 3.03 | 2.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying PAHC stock.
Phibro Animal Health Corporation's current P/E is 36.3x. The average P/E over the last 4 quarters is 13.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Phibro Animal Health Corporation's current operating margin is 8.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Phibro Animal Health Corporation's business trajectory between earnings reports.